Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chenyue Zhang

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Scandinavian Journal of Clinical and Laboratory Investigation|April 24, 2023
Expression pattern of <i>miR-16-2-3p</i> and its prognostic values on pediatric acute lymphoblastic leukemiaXinran Chu, Dong Wu, Chenyue Zhang, et al.
Oncology Letters|January 25, 2019
Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinomaPeisi Kou, Chenyue Zhang, Jiamao Lin, et al.
Oncotarget|October 15, 2017
The appropriate number of ELNs for lymph node negative breast cancer patients underwent MRM: a population-based studyHuiying Chi, Chenyue Zhang, Haiyong Wang, et al.
Journal of Translational Medicine|July 14, 2023
Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directionsChenyue Zhang, Chenxing Zhang, Kai Wang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 20, 2018
Circular RNA Hsa_Circ_0091579 Serves as a Diagnostic and Prognostic Marker for Hepatocellular CarcinomaChenxing Zhang, Chenyue Zhang, Jiamao Lin, et al.
Future Oncology (London, England)|September 6, 2022
Non-small-cell lung cancer patients harboring <i>TP53/KRAS</i> co-mutation could benefit from a PD-L1 inhibitorChenyue Zhang, Kai Wang, Jiamao Lin, et al.
Journal of Thoracic Disease|February 9, 2026
Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world studyHaoyu Wang, Chenyue Zhang, Shanshan Du, et al.
Frontiers in Oncology|December 19, 2019
Surgery as a Potential Treatment Option for Patients With Stage III Small-Cell Lung Cancer: A Propensity Score Matching AnalysisChenyue Zhang, Cheng Li, Xiaoling Shang, et al.
Cancer Cell International|December 29, 2020
CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinomaChenyue Zhang, Hui Wang, Xia Wang, et al.
The Oncologist|September 14, 2023
Construction of a Diagnostic Model for Small Cell Lung Cancer Combining Metabolomics and Integrated Machine LearningXiaoling Shang, Chenyue Zhang, Ronghua Kong, et al.
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Scandinavian Journal of Clinical and Laboratory Investigation|April 24, 2023
Expression pattern of <i>miR-16-2-3p</i> and its prognostic values on pediatric acute lymphoblastic leukemiaXinran Chu, Dong Wu, Chenyue Zhang, et al.
Oncology Letters|January 25, 2019
Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinomaPeisi Kou, Chenyue Zhang, Jiamao Lin, et al.
Oncotarget|October 15, 2017
The appropriate number of ELNs for lymph node negative breast cancer patients underwent MRM: a population-based studyHuiying Chi, Chenyue Zhang, Haiyong Wang, et al.
Journal of Translational Medicine|July 14, 2023
Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directionsChenyue Zhang, Chenxing Zhang, Kai Wang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 20, 2018
Circular RNA Hsa_Circ_0091579 Serves as a Diagnostic and Prognostic Marker for Hepatocellular CarcinomaChenxing Zhang, Chenyue Zhang, Jiamao Lin, et al.
Future Oncology (London, England)|September 6, 2022
Non-small-cell lung cancer patients harboring <i>TP53/KRAS</i> co-mutation could benefit from a PD-L1 inhibitorChenyue Zhang, Kai Wang, Jiamao Lin, et al.
Journal of Thoracic Disease|February 9, 2026
Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world studyHaoyu Wang, Chenyue Zhang, Shanshan Du, et al.
Frontiers in Oncology|December 19, 2019
Surgery as a Potential Treatment Option for Patients With Stage III Small-Cell Lung Cancer: A Propensity Score Matching AnalysisChenyue Zhang, Cheng Li, Xiaoling Shang, et al.
Cancer Cell International|December 29, 2020
CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinomaChenyue Zhang, Hui Wang, Xia Wang, et al.
The Oncologist|September 14, 2023
Construction of a Diagnostic Model for Small Cell Lung Cancer Combining Metabolomics and Integrated Machine LearningXiaoling Shang, Chenyue Zhang, Ronghua Kong, et al.
Pageof 10